TLC-ART has proposed and received NIH funding to begin human testing of our 3-drug combination HIV medicines. Current long-acting HIV treatments use only one drug. TLC-ART’s goal is to transform short-acting HIV drugs into long-acting combinations that target the virus in the blood and lymphs.
Dr. Ann Collier together with Dr. Rodney Ho are leading this FIH program.